← All stocks

HYPERION DEFI, INC.

HYPD Net buying
CIK 0001682639 #4713 in the set updated 19 Sep 2026
Bought (120 mo)
$18.24M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$1.28M
$1.28M on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 5 sales
Net
+$16.97M
+$18.24M against sales at will

By person

24 insiders · 134 transactions

There is no salary here to measure against. HYPERION DEFI, INC.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Grant Stuart M.
10% owner
$9.46M (58)
+$9.46M
10,914,153
$40.16M
+76.9%
ESHELMAN FREDRIC N
Director
$3.35M (1)
+$3.35M
1,618,835
$5.96M
+28.7%
MARIO ERNEST
Director
$1.19M (3)
+$1.19M
382,706
$1.41M
+258.5%
Senju Pharmaceutical Co., Ltd. entity
10% owner
$1.00M (1)
+$1.00M
1,718,566
$6.32M
+6.2%
Yoshida Shuhei
Director
$1.00M (1)
+$1.00M
1,751,900
$6.45M
+8.2%
Strahlman Ellen R
Director
$309.66K (12)
+$309.66K
184,947
$680.60K
Walters Happy David
Director
$187.15K (1)
+$187.15K
170,847
$628.72K
Ianchulev Tsontcho
Director
$1.10M (5)
$1.28M (5) scheduled
−$176.90K
622,791
$2.29M
+18.9%
LaBelle Curt H
Director
$150.00K (2)
+$150.00K
648,903
$2.39M
−29.5%
Knox David R.
Chief Financial Officer
$100.34K (1)
+$100.34K
307,119
$1.13M
MATHER CHARLES E IV
Director
$96.44K (8)
+$96.44K
9,953
$36.63K
Rowe Michael M
Chief Executive Officer
$90.87K (12)
+$90.87K
7,975
$29.35K
GELTZEILER MICHAEL S
Director
$90.21K (1)
+$90.21K
146,932
$540.71K
LEE KENNETH B JR
Director
$54.51K (4)
+$54.51K
64,544
$237.52K
GANDOLFO JOHN P
Chief Financial Officer
$30.90K (3)
+$30.90K
8,000
$29.44K
Jung Hyunsu
See Remarks
$29.58K (4)
+$29.58K
1,345,676
$4.95M
Kern Bren
Chief Operating Officer
$6.83K (1)
+$6.83K
50,031
$184.11K
JACOBSON RACHEL
Director
115,218
$424.00K
Rubenstein Robert
General Counsel
75,000
$276.00K
Clasby Jennifer G
VP, Regulatory and Clinical
65,950
$242.70K
Haller Julia A
Director
30,408
$111.90K
SUN ANTHONY Y
Director
26,322
$96.86K
Benjamin Stephen Keith
Director
25,511
$93.88K
Palanki Ram
Director
4,236
$15.59K

No percentages here. This company's share count has moved by a factor of 30.5 over the window, from 2,830,546 to 86,441,611 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Rowe Michael M
1 May 2023
Chief Executive Officer
Exercised, kept
10,000
$2.72
$27.20K
Clasby Jennifer G
17 Jun 2021
VP, Regulatory and Clinical
Exercised, kept
24,510
$1.95
$47.79K
MARIO ERNEST
15 Jan 2021
Director
Exercised, kept
41,216
$2.27
$93.56K
Ianchulev Tsontcho
5 Jan 2021
Chief Executive Officer
Exercised, kept
41,216
$2.27
$93.56K
Clasby Jennifer G
18 Sep 2020
VP, Clinical Operations
Exercised, kept
26,737
$1.95
$52.14K
Yoshida Shuhei
14 May 2019
Director
Exercised, kept
33,334
$1.95
$65.00K
Ianchulev Tsontcho
2 Jan 2019
Chief Executive Officer
Exercised, kept indirect
140,000
$1.24
$173.60K
Ianchulev Tsontcho
2 Jan 2019
Chief Executive Officer
Exercised, kept
133,686
$1.95
$260.69K
Ianchulev Tsontcho
2 Jan 2019
Chief Executive Officer
Exercised, kept
40,000
$1.24
$49.60K
LaBelle Curt H
2 Jan 2019
Director
Exercised, kept indirect
140,000
$1.24
$173.60K
Clasby Jennifer G
10 Sep 2018
VP, Clinical Operations
Exercised, kept
28,965
$1.95
$56.48K

What was left out

Form 4 filings counted 194
Amendments (4/A) skipped 10
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 5
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 4,983,345
History held since 6 Feb 2018